Vivek Subbiah, MD

@matteolambe @OncoAlert @UniGenova Huge congratulations 🎉🎉🎉!!!

May 4, 2026 Today is a truly special day, one to remember. I am deeply honored to take on the role of Director of Medical Oncology at Galliera Hospital in Genoa. Thank you so much to all those who have supported me in reaching this important milestone ! @OncoAlert @UniGenova

🔟 Must-Read in GI Oncology | Apr 27–May 3 A week of momentum across early-phase innovation, translational science, and real-world evidence👇 🔬 Highlights: • COMPANION-002: PFS + ORR improvement in BTC • MONTBLANC: Phase II HCC fully enrolled • COLOSOTO: Fast enrollment (KRAS G12C mCRC) • mFOLFOXIRI → CRT: ORR 30.8%, pCR 20.5% (LARC) • CEA-directed T cell engager + 4-1BB: MSS CRC strategy • Nano-273: overcoming IO resistance (preclinical) • Anal cancer cohort: CRT outcomes • CME meta-analysis: survival benefit • FDA early access: pancreatic cancer • Risk models: earlier detection 💡 Takeaway: Progress is driven by early-phase + translational + real-world convergence. @VivekSubbiah @RashidLui @staclinds @DuxinSun @N_BenKhaled @JuliaMayerle @EnricoNDeToni @forghy @JMarescauxIrcad @ElieRassy @StefanMichiels @TPudlarz @david_tougeron 📎oncodaily.com/oncolibrary/10… #GIOncology #Oncology #CancerResearch #Immunotherapy #CRC #PancreaticCancer #HCC #BTC #ClinicalTrials #OncoDaily

Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment | JCO Precision Oncology ascopubs.org/doi/10.1200/PO…

🚨⭐️Effect of one or two cycles of dual immunotherapy with nivolumab and ipilimumab in patients with mismatch repair-deficient rectal cancer (RESET-R): interim results from a multicentre, single-arm, phase 2 trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

CC @VivekSubbiah

🚨 Another FDA announcement regarding a new drug for #PancreaticCancer @RevMedicines @OncBrothers #OncTwitter #MedTwitter #MedX #gism

We remain committed to pursuing science that may help address significant unmet needs and contribute to the future of treatment innovation.

TWO DAYS after receiving the application, FDA greenlit the new pancreatic cancer drug daraxonrasib for expanded access. This drug has also been granted a national priority voucher, which means a full application could be reviewed in a matter of weeks instead of 10-12 months.

Hats off to @slernerbcmedu1 @bcmhouston for leading yet another spectacular #SWOGspring2026 GU closed session. No slides here (all concepts confidential!) but was encouraging to see wonderful designs presented by @AbhiTrip87, @monda_steven, @ShuchiGulati, @umangtalking, @theusinghal, @arnabguonc & so many others. And a HUGE congrats to @neerajaiims on being appointed to the @SWOG Executive Committee!

🚨⭐️Wow! It’s BIG news on Friday 👉🏼 F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer👉🏼 Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives @nytimes @OncoAlert @OpenMedicineHQ @oncodaily @DavidHongMD @Aiims1742 @RevMedicines nytimes.com/2026/05/01/bus…

⭐️🚨It’s Friday & we have a new FDA approval 👉🏼FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer #precisionmedicine @OncoAlert @MedwatchKate @oncodaily fda.gov/drugs/resource…

Island Prime with Dihua and Ping, Philip, Vivek Subbiah and Jenny Liu at AACR. Excellent colleagues and friends from MD Anderson, Australia and Stanford

@Dr_R_Kurzrock Love this team🎉🎉🎉

SWOG in San Francisco. With our committee vice chair Young Chae and our committee statistician Megan Othus. I love SWOG. DART immunotherapy trial opened at over 1000 sites— only cooperative groups can do that

⭐️$100 genome was just the warm‑up. Next comes the $1 genome…….. and then the $1 point‑of‑care genome……instant, accessible, democratized. #Precision medicine for all. Genomics IS the diagnosis @oncodaily @OncoAlert ascopubs.org/doi/10.1200/JC…

The cost of sequencing a human genome dropped from $100M to less than $100 in about 25 years. That's a million-fold decrease, which outpaces even Moore's Law. We're about to enter the era of personalized medicine.

Now online: Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRAS G12C -Mutant NSCLC for Immune Checkpoint Blockade doi.org/10.1158/2159-8…

Now online: A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth doi.org/10.1158/2159-8…

⭐️Enabling a new model for healthcare with AI co-clinician @GoogleDeepMind @pushmeet deepmind.google/blog/ai-co-cli…

FDA ODAC Votes Against Clinical Benefit of Switching to Camizestrant in HR+ Breast Cancer After ESR1 Mutation Detection | OncLive onclive.com/view/fda-odac-…